Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) EBITDA (2020 - 2025)

Apellis Pharmaceuticals has reported EBITDA over the past 6 years, most recently at -$58.7 million for Q4 2025.

  • Quarterly results put EBITDA at -$58.7 million for Q4 2025, down 60.6% from a year ago — trailing twelve months through Dec 2025 was $23.6 million (up 111.94% YoY), and the annual figure for FY2025 was $23.6 million, up 111.94%.
  • EBITDA for Q4 2025 was -$58.7 million at Apellis Pharmaceuticals, down from $215.9 million in the prior quarter.
  • Over the last five years, EBITDA for APLS hit a ceiling of $215.9 million in Q3 2025 and a floor of -$219.4 million in Q2 2021.
  • Median EBITDA over the past 5 years was -$130.5 million (2022), compared with a mean of -$105.2 million.
  • Biggest five-year swings in EBITDA: crashed 285.23% in 2021 and later skyrocketed 477.27% in 2025.
  • Apellis Pharmaceuticals' EBITDA stood at -$148.0 million in 2021, then fell by 10.69% to -$163.8 million in 2022, then soared by 44.43% to -$91.1 million in 2023, then soared by 59.89% to -$36.5 million in 2024, then plummeted by 60.6% to -$58.7 million in 2025.
  • The last three reported values for EBITDA were -$58.7 million (Q4 2025), $215.9 million (Q3 2025), and -$41.7 million (Q2 2025) per Business Quant data.